Prominent publications by Shi Bo Jiang

KOL Index score: 19596

Middle East respiratory syndrome coronavirus (MERS-CoV) currently spreads in humans and causes ∼ 36% fatality in infected patients. Believed to have originated from bats, MERS-CoV is genetically related to bat coronaviruses HKU4 and HKU5. To understand how bat coronaviruses transmit to humans, we investigated the receptor usage and cell entry activity of the virus-surface spike proteins of HKU4 and HKU5. We found that dipeptidyl peptidase 4 (DPP4), the receptor for MERS-CoV, is also the ...

Also Ranks for: Mers Coronavirus |  receptor usage |  cell entry |  dipeptidyl peptidase |  human dpp4
KOL Index score: 16562

Middle East respiratory syndrome coronavirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein receptor-binding domain (RBD). The RBD contains critical neutralizing epitopes and serves as an important vaccine target. Since RBD mutations occur in different MERS-CoV isolates and antibody escape mutants, cross-neutralization of divergent MERS-CoV strains by RBD-induced antibodies remains unknown. Here, we constructed four recombinant RBD (rRBD) ...

Also Ranks for: Neutralizing Antibodies |  middle east |  mers cov |  protein binding |  vaccine target
KOL Index score: 15654

The recently discovered Middle East respiratory syndrome coronavirus (MERS-CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics and vaccines against the MERS-CoV are urgently needed to save human lives and address the pandemic concerns. We identified three human monoclonal antibodies (MAbs), m336, m337, and m338, targeting the receptor (CD26/DPP4) binding domain (RBD) of the MERS-CoV spike glycoprotein from a very large naïve-antibody library ...

Also Ranks for: Monoclonal Antibodies |  middle east |  respiratory syndrome |  potent neutralization |  mers cov
KOL Index score: 15303

The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, ...

Also Ranks for: Rbd Protein |  viral attachment |  2019 coronavirus |  cov2 sars |  binding domain
KOL Index score: 14895

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) continues to infect humans and camels, calling for efficient, cost-effective, and broad-spectrum strategies to control its spread. Nanobodies (Nbs) are single-domain antibodies derived from camelids and sharks and are potentially cost-effective antivirals with small size and great expression yield. In this study, we developed a novel neutralizing Nb (NbMS10) and its human-Fc-fused version (NbMS10-Fc), both of which ...

Also Ranks for: Middle East |  binding domain |  mers cov |  neutralizing antibodies |  respiratory syndrome
KOL Index score: 14745

Fuzeon (also known as T-20 or enfuvirtide), one of the C-peptides derived from the HIV-1 envelope glycoprotein transmembrane subunit gp41 C-terminal heptad repeat (CHR) region, is the first member of a new class of anti-HIV drugs known as HIV fusion inhibitors. It has been widely believed that T-20 shares the same mechanism of action with C34, another C-peptide. The C34 is known to compete with the CHR of gp41 to form a stable 6-helix bundle (6-HB) with the gp41 N-terminal heptad repeat ...

Also Ranks for: Hiv Fusion |  gp41 gp120 |  nhr region |  c34 chr |  envelope protein
KOL Index score: 14282

The spike (S) protein of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is a major antigenic determinant capable of inducing protective immunity. Recently, a small fragment on the SARS-CoV S protein (residues 318-510) was characterized as a minimal receptor-binding domain (RBD), which mediates virus binding to angiotensin-converting enzyme 2, the functional receptor on susceptible cells. In this study, we demonstrated that a fusion protein containing RBD linked to ...

Also Ranks for: Coronavirus Spike |  monoclonal antibodies |  viral antigens |  rbd protein |  potent neutralizing
KOL Index score: 14109

T20 (Fuzeon), a novel anti-human immunodeficiency virus (HIV) drug, is a peptide derived from HIV-1 gp41 C-terminal heptad repeat (CHR). Its mechanism of action has not yet been defined. We applied Pepscan strategy to determine the relationship between functional domains and mechanisms of action of five 36-mer overlapping peptides with a shift of five amino acids (aa): CHR-1 (aa 623-658), C36 (aa 628-663), CHR-3 (aa 633-668), T20 (aa 638-673), and CHR-5 (aa 643-678). C36 is a peptide ...

Also Ranks for: Functional Domains |  hiv gp41 |  peptide t20 |  heptad repeat |  mechanisms action
KOL Index score: 13939

We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse ...

Also Ranks for: Spike Protein |  intranasal vaccination |  immune responses |  respiratory syndrome |  binding domain
KOL Index score: 13765

The recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health. To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be defined. Therefore, we herein established a SARS-CoV-2 spike (S) protein-mediated cell-cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of ...

Also Ranks for: Membrane Fusion |  spike protein |  sarscov2 sarscov |  cov2 infection |  highly potent
KOL Index score: 13506

The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge. The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry. Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, especially in the respiratory ...

Also Ranks for: Candidate Receptor |  cov2 sars |  spike glycoprotein |  epithelial cells |  viral entry
KOL Index score: 13238

Importance: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The association between clinical characteristics of the virus and neutralizing antibodies (NAbs) against this virus have not been well studied.

Objective: To examine the association between clinical characteristics and levels of NAbs in patients who recovered from COVID-19.

Design, Setting, and Participants: In this cohort ...

Also Ranks for: Nab Titers |  clinical characteristics |  coronavirus disease covid19 |  sars cov |  antibodies neutralizing
KOL Index score: 13236

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) ...

Also Ranks for: Intranasal Vaccination |  immune responses |  neutralizing antibodies |  spike protein |  middle east
KOL Index score: 13224

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important ...

Also Ranks for: Sars Coronavirus |  human monoclonal |  spike protein |  2019 ncov |  potent binding

Key People For Neutralizing Antibodies

Top KOLs in the world
John * *******
neutralizing antibodies immunodeficiency virus nonhuman primates
Barney * ******
respiratory syncytial virus neutralizing antibodies dna vaccine
Dennis ******* ******
neutralizing antibodies hiv envelope immunodeficiency virus
Peter * *****
neutralizing antibodies cd4 binding fusion peptide
Ian * ******
crystal structure neutralizing antibodies influenza virus
Michel * ***********
dendritic cells neutralizing antibodies somatic hypermutation

Shi Bo Jiang:Expert Impact

Concepts for whichShi Bo Jianghas direct influence:Neutralizing antibodies,  Monoclonal antibodies,  Spike protein,  Middle east,  Fusion inhibitors,  Spike glycoprotein,  Hiv fusion,  Influenza virus.

Shi Bo Jiang:KOL impact

Concepts related to the work of other authors for whichfor which Shi Bo Jiang has influence:Spike protein,  Neutralizing antibodies,  Influenza virus,  Respiratory syndrome,  Sarscov2 infection,  Immune response,  Vaccine development.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China | Key Laboratory of Medical Molecular Viro